91 related articles for article (PubMed ID: 11366737)
1. Interleukin-2 (IL-2, Proleukin).
Proj Inf Perspect; 1999 Apr; (27):21-2. PubMed ID: 11366737
[TBL] [Abstract][Full Text] [Related]
2. Improved treatment results with interleukin-2.
HIV Hotline; 1998 May; 8(2):13-4. PubMed ID: 11365363
[TBL] [Abstract][Full Text] [Related]
3. IL-2 taken to HAART.
Gilden D
GMHC Treat Issues; 1999 Feb; 13(2):4-6. PubMed ID: 11366116
[TBL] [Abstract][Full Text] [Related]
4. IL-2 study results in confusion.
TreatmentUpdate; 1999 Jul; 11(5):4-6. PubMed ID: 11366929
[TBL] [Abstract][Full Text] [Related]
5. Immune based therapy update.
Proj Inf Perspect; 1998 Sep; (25):17-9. PubMed ID: 11365845
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-2 clinical trials.
Newsline People AIDS Coalit N Y; 1998 Sep; ():58. PubMed ID: 11367495
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119).
Molina JM; Levy Y; Fournier I; Hamonic S; Bentata M; Beck-Wirth G; Gougeon ML; Venet A; Madelaine I; Sereni D; Jeanblanc F; Boulet T; Simon F; Aboulker JP;
J Infect Dis; 2009 Jul; 200(2):206-15. PubMed ID: 19508157
[TBL] [Abstract][Full Text] [Related]
8. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial--AIDS Clinical Trials Group 328.
Mitsuyasu R; Gelman R; Cherng DW; Landay A; Fahey J; Reichman R; Erice A; Bucy RP; Kilby JM; Lederman MM; Hamilton CD; Lertora J; White BL; Tebas P; Duliege AM; Pollard RB;
Arch Intern Med; 2007 Mar; 167(6):597-605. PubMed ID: 17389292
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of HIV infections with antiretroviral drugs and recombinant interleukin-2].
Dragsted UB; Afzelius P; Nielsen SD; Lundgren JD
Ugeskr Laeger; 2000 Oct; 162(42):5614-8. PubMed ID: 11059298
[TBL] [Abstract][Full Text] [Related]
10. Two years of IL-2 in early HIV disease--fantastic increases in CD4+ cell counts.
TreatmentUpdate; 1999 Mar; 11(2):4-5. PubMed ID: 11366777
[TBL] [Abstract][Full Text] [Related]
11. [The role of therapeutic use of interleukin-2 in HIV infection].
Knysz B; Gasiorowski J; Inglot M; Rymer W; Szymczak A; Gładysz A
Przegl Epidemiol; 2002; 56(4):587-93. PubMed ID: 12666584
[TBL] [Abstract][Full Text] [Related]
12. Increase of HIV-1 pro-viral DNA per million peripheral blood mononuclear cells in patients with advanced HIV disease (CD4<200 cells/mm3) receiving interleukin 2 combined with HAART versus HAART alone (ANRS-082 trial).
Delaugerre C; Gourlain K; Tubiana R; Carcelain G; Marcelin AG; Chouquet C; Mouroux M; Duvivier C; Autran B; Costagliola D; Katlama C; Calvez V
Antivir Ther; 2003 Jun; 8(3):233-7. PubMed ID: 12924540
[TBL] [Abstract][Full Text] [Related]
13. A study of rectal mucosa administration of IL-2 in treatment of HIV/AIDS: a novel method for the treatment of HIV/AIDS.
Zhang K; Xing H; Ren Y; Lu ZZ; Hou YD
AIDS; 2008 Oct; 22(16):2222-4. PubMed ID: 18832891
[No Abstract] [Full Text] [Related]
14. Long-term effects of intermittent interleukin-2 therapy in chronic HIV-infected patients (ANRS 048-079 Trials).
Durier C; Capitant C; Lascaux AS; Goujard C; Oksenhendler E; Poizot-Martin I; Viard JP; Weiss L; Netzer E; Delfraissy JF; Aboulker JP; Lévy Y
AIDS; 2007 Sep; 21(14):1887-97. PubMed ID: 17721096
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blinded, placebo-controlled trial of intermittent administration of interleukin-2 and prednisone in subjects infected with human immunodeficiency virus.
Tavel JA; Sereti I; Walker RE; Hahn B; Kovacs JA; Jagannatha S; Davey RT; Falloon J; Polis MA; Masur H; Metcalf JA; Stevens R; Rupert A; Baseler M; Lane HC
J Infect Dis; 2003 Aug; 188(4):531-6. PubMed ID: 12898439
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-2 (IL-2): a path toward functional eradication?
Proj Inf Perspect; 1998 Dec; (26):20-1. PubMed ID: 11366494
[TBL] [Abstract][Full Text] [Related]
17. Stopping HAART after one year.
TreatmentUpdate; 1999 Jul; 11(5):3-4. PubMed ID: 11366928
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2 for the treatment of HIV infection.
Simmons P
Res Initiat Treat Action; 1999 Apr; 5(2):17-21. PubMed ID: 11366280
[TBL] [Abstract][Full Text] [Related]
19. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
20. Long-term clinical and surrogate marker effects of subcutaneous intermittent interleukin-2 without antiretroviral therapy in HIV-infected patients.
Herzmann C; Cuthbertson Z; Fosdick L; Fisher M; Nelson M; Perry N; Law M; Wand H; Janossy G; Johnson MA; Youle M
J Antimicrob Chemother; 2008 Sep; 62(3):583-6. PubMed ID: 18587135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
